INSERM U1148, Laboratory for Vascular Translational Science, X. Bichat Hospital, Paris Diderot University, Paris 13 University, 75018, Paris, France.
Institut Galien, Université Paris-Sud, UMR CNRS 8612, University Paris Saclay, 92290, Chatenay Malabry, France.
Adv Mater. 2018 Sep;30(37):e1707365. doi: 10.1002/adma.201707365. Epub 2018 Jun 6.
In the past few years, numerous studies have demonstrated the great potential of nano particles of metal-organic frameworks (nanoMOFs) at the preclinical level for biomedical applications. Many of them were reported very recently based on their bioactive composition, anticancer application, or from a general drug delivery/theranostic perspective. In this review, the authors aim at providing a global view of the studies that evaluated MOFs' biomedical applications at the preclinical stage, when in vivo tests are described either for pharmacological applications or for toxicity evaluation. The authors first describe the current surface engineering approaches that are crucial to understand the in vivo behavior of the nanoMOFs. Finally, after a detailed and comprehensive analysis of the in vivo studies reported with MOFs so far, and considering the general evolution of the drug delivery science, the authors suggest new directions for future research in the use of nanoMOFs for biomedical applications.
在过去的几年中，大量研究表明，金属有机骨架（nanoMOFs）的纳米颗粒在生物医学应用方面具有巨大的潜力。其中许多研究是基于它们的生物活性成分、抗癌应用或从一般的药物输送/治疗的角度来进行的，并且最近才报道。在这篇综述中，作者旨在提供一个全面的视角，评估在临床前阶段评估 MOFs 生物医学应用的研究，此时体内测试是针对药理学应用或毒性评估来描述的。作者首先描述了目前的表面工程方法，这些方法对于理解纳米 MOFs 的体内行为至关重要。最后，在对迄今为止报道的与 MOFs 相关的体内研究进行详细和全面的分析后，并考虑到药物输送科学的总体发展，作者为未来使用纳米 MOFs 进行生物医学应用的研究提出了新的方向。
